Recurrent breast cancer
Clinical trials for Recurrent breast cancer explained in plain language.
Never miss a new study
Get alerted when new Recurrent breast cancer trials appear
Sign up with your email to follow new studies for Recurrent breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a targeted drug boost hormone therapy against breast cancer?
Disease control CompletedThis trial is testing whether adding an experimental drug called BYL719 to standard hormone therapy (letrozole) can better fight hormone receptor-positive metastatic breast cancer in post-menopausal women. BYL719 targets a protein that helps cancer cells grow, while letrozole blo…
Matched conditions: RECURRENT BREAST CANCER
Phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Triple threat: new combo shows promise against tough breast cancer
Disease control CompletedThis phase II trial tested a combination of two targeted antibodies (pertuzumab and trastuzumab) plus a chemotherapy drug (nab-paclitaxel) in 63 patients with HER2-positive advanced breast cancer. The goal was to see how well the drugs work together to stop tumor growth and impro…
Matched conditions: RECURRENT BREAST CANCER
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy for advanced breast cancer shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called ONO-4578 combined with standard hormone therapy and targeted drugs (letrozole plus palbociclib or abemaciclib) in 46 postmenopausal women with advanced or recurrent hormone receptor-positive, HER2-negative breast cancer. The main go…
Matched conditions: RECURRENT BREAST CANCER
Phase 1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo shows promise in Hard-to-Treat breast cancer
Disease control CompletedThis study tested a new drug called taselisib combined with standard anti-HER2 therapies in 68 people with advanced HER2+ breast cancer. The goal was to find the safest dose and see if the combination could shrink tumors or slow the disease. While not a cure, the approach aims to…
Matched conditions: RECURRENT BREAST CANCER
Phase 1 • Sponsor: Otto Metzger, MD • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC